Medicare Part B Rx Vendors Should Cover All Single Source Drugs, BIO Says
Executive Summary
Medicare should require Part B drug vendors to offer at least one formulation of each single-source drug and biologic under the competitive acquisition program, the Biotechnology Industry Organization said
You may also be interested in...
CMS Could Award Up To 250 Part B Rx Contracts Under Bidding Program
Medicare could award anywhere from five to 250 separate Part B drug vendor contracts under the competitive acquisition program depending on how the Centers for Medicare & Medicaid Services ends up defining bidding areas
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials